Making Sense of the Current SPAC Market: Are SPACs still a viable pathway to going public? hosted by BIO

Description

Within the past year the role in biotech of special purpose acquisition companies (SPAC) has moved from a rarefied interest to a core option for reaching public markets, now attracting high levels of investor and regulator attention. Learn through live Q&A with a panel of SPAC deal experts how this popular, volatile tool for raising capital works in practice and will evolve next.

Sponsored by Chardan

Moderator: Barbara Ryan, Founder, Barbara Ryan Advisors; Editorial Advisory Board, Pharmaceutical Executive; Senior Advisor, EY

Panelists:

• Jonas Grossman, President and Managing Partner, Chardan
• Rakhi Kumar, Chief Accounting Officer, Roivant Sciences
• Ryan Maierson, Partner, Latham & Watkins LLP
• Carlo Passeri, Director, Biotechnology Capital Markets, Biotechnology Innovation Organization (BIO)